Results Briefing Analyst Presentation 4Q & FY2018

© All Rights Reserved.

This material is confidential and property to IHH Healthcare Berhad. No part of this material

should be reproduced or published in any form by any means, nor should the material be

disclosed to third parties without the consent of IHH.

Results Briefing Analyst Presentation

4Q & FY2018

27 February 2019

2

Disclaimer

This document is and shall remain the exclusive property of IHH Healthcare Berhad (the “Company”) and nothing herein shall give, or shall be construed

as giving, to any party any right, title, ownership, interest, licence or any other right whatsoever in or to this document. Neither this document nor any part

thereof may be (i) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (ii) redistributed, passed on or otherwise

disseminated, without the Company’s permission. Although care has been taken to ensure that the information in this document is accurate, and that the opinions expressed are fair and reasonable, the

information is subject to change without notice, its accuracy is not guaranteed, has not been independently verified and it may not contain all material

information concerning the Company and its subsidiaries and associate companies. None of the Company nor its subsidiaries or associate companies nor

any of its or their respective members, directors, officers, employees, affiliates or advisors make any representation or warranty (express or implied)

regarding, nor assumes any responsibility or liability for, the accuracy, reasonableness, fairness or completeness of, or any errors or omissions in, any

information contained herein. Accordingly, none of the above nor any other person accepts any liability (in negligence, or otherwise) for any loss arising

from or in connection with any use of this document or its contents. This document is for information purposes only and does not constitute or form part of any offer or invitation by or on behalf of the Company for sale or

subscription of or solicitation or invitation of any offer to or recommendation to buy or subscribe for any securities (“Securities”), nor shall it or any part of it

form the basis of or be relied on in connection with any contract, commitment or investment decision in relation to the Securities of the Company in

Malaysia, Singapore or any other jurisdiction. The information in this document does not take into consideration the investment objectives, financial

situation or particular needs of any particular investor, and should not be treated as giving investment advice. In addition, this document contains certain financial information and results of operation, and may also contain certain projections, plans, strategies, and

objectives of the Company, that are not statements of historical fact which would be treated as forward looking statements that reflect the Company’s

current views with respect to future events and financial performance. These views are based on a number of estimates and current assumptions which are

subject to business, economic, political and competitive uncertainties and contingencies as well as various risks which are in many cases outside the

control of the Company, and which may change over time and may cause actual events and the Company’s future results to be materially different than

expected or indicated by such statements. No assurance can be given that future events will occur, that projections will be achieved, or that the Company’s

assumptions are correct. Such forward‐looking statements are not guarantees of future performance and accordingly, the actual results, financial condition,

performance or achievements of the Company may differ materially from those anticipated by the Company in the forward looking statements. You are

cautioned not to place undue reliance on these forward looking statements. The Company does not undertake to provide you with access to any additional information or to update the information contained in the document or to

correct any inaccuracies therein which may become apparent.

3

Key Highlights for Q4 2018

Sustained organic growth; Double-digit revenue and EBITDA growth • Q4 2018 revenue up 10% year-on-year to RM3.2 billion; EBITDA up 18% to

RM724.1 million. On constant currency terms, growth was 28% and 33% respectively • PATMI (Excl EI) at RM341.5 million in Q4 2018 driven by stronger operational performance

and boosted by the FX gains from the USD denominated cash balances

Strong balance sheet with prudent cash management: • Net gearing of 0.10 times with RM7.8 billion cash position • Net cash generated from operating activities remained strong at RM1.9 billion for FY 2018 • Board recommends dividend of 3 sen per ordinary share

Revenue

RM3.2 b (↑ 10%)

EBITDA

RM724.1 m (↑ 18%)

PATMI

RM509.4 m (↑ 403%)

PATMI (Excl EI)

RM341.5 m (↑ 88%)

Focused on stabilising performance at Fortis: • Became controlling shareholder after completing preferential allotment in November

2018; appointed 5 members to the Fortis Board • Completed acquisition of RHT Health Trust’s assets for INR46,663 million (~RM2.7 billion) • New CEO appointed in Dr Ashutosh Raghuvanshi; New CFO appointed in Mr Vivek Goyal





4

Financial Highlights

5

Sustained organic growth from existing operations

YoY growth eroded by stronger RM

RM'mil 2018 2017 Variance 2018 2017 Variance

Revenue 3,165.3 2,885.1 10% 11,520.9 11,142.6 3%

EBITDA 724.1 615.7 18% 2,477.7 2,279.5 9%

PATMI 509.4 101.3 NM 627.7 970.0 -35%

PATMI (Excl EI) 341.5 181.9 88% 1,027.6 595.3 73%

QTD Dec YTD DecTotal Group Results

Q4 Commentary

• Higher revenue due to:

• Sustained organic growth from existing operations

• Continuous ramp up of Gleneagles Hong Kong and Acibadem Altunizade

• Contribution from newly acquired Amanjaya and Fortis

• Higher EBITDA driven by stronger operational performance across the home markets

• On constant currency, Revenue and EBITDA increased 28% and 33% respectively

• PATMI excluding exceptional items increased due to stronger operational performance and boosted by FX

gains from the USD denominated cash balances

6

Exceptional Items


Profit after tax and minority interests 509.4 101.3 NM 627.7 970.0 -35%

Add back/(Less): Exceptional Items

Gain on disposal of a subsidiary1

- (1.1) - (1.1)

Gain on dispoal of quoted AFS financial instruments2

- - - (554.5)

(Gain)/Loss on disposal business units (2.9) (0.2) (2.9) 0.8

Change in fair value of investment properties3

(23.8) (16.5) (23.8) (16.5)

Change in fair value of call option4

(17.2) 4.8 (17.2) 4.8

Change in fair value of CCPS liabilities5

- 13.8 - 13.8

Change in fair value of put option (2.1) - (2.1)

Impairment loss on goodwill 66.2 - 66.2 -

Impairment loss on investment in a joint venture6

33.4 - 33.4 -

2.8 0.4 4.0 1.6

Investment tax allowance8

- (2.5) - (2.5)

Insurance compensation for Chennai flood 0.1 - (17.2) -

Professional fees relating to an acquisition9

- - 3.7 -

Exchange (gain)/loss on net borrowings10

(457.4) 176.9 644.1 379.2

(401.0) 175.4 688.1 (174.7)

Add/(less): Tax effects on exceptional items 67.4 (35.4) (73.4) (75.8)

(333.5) 140.0 614.7 (250.5)

Add/(less): Minority interest share of exceptional items 165.7 (59.4) (214.8) (124.2)

(167.9) 80.6 399.9 (374.6)

341.5 181.9 88% 1,027.6 595.3 73%

(33.9) (21.6) (85.8) (76.1)

307.7 160.3 92% 941.8 519.2 81%

YTD DecQTD Dec

Profit after tax and minority interests

(Excluding exceptional items11

)

Less: PATMI contribution from PLife REIT

Profit after tax and minority interests

(Excluding exceptional items11

and PLife REIT)

Provision for financial guarantee given on a joint venture's loan

facility7

7

Exceptional Items Note:

1) Gain on disposal of 60% interest in SESU Ozel Saglik Hizmetleri Tibbi Malzemeler ve Ticaret A.S. during 2017

2) Gain on disposal of the Group’s 4.78% and 6.07% interest in Apollo Hospital Enterprise Limited in May 2017 and March 2017

respectively

3) Change in fair valuation of investment properties held for rental to third parties, excluding PLife REIT’s investment properties

held for rental to third parties

4) Change in fair value of call option right granted to non-controlling interests of a subsidiary to purchase the Group's 3%

interest in the subsidiary on a fully diluted basis, at a fixed price of INR500.0 million upon the non-achievement of certain

financial targets

5) Change in fair value of Compulsory Convertible Preference Shares ("CCPS") of a subsidiary that were classified as liabilities

in 2017

6) Impairment loss on investment in Khubchandani Hospitals

7) Proportionate share of corporate guarantee in relation to accrued interest on Khubchandani Hospital's loan

8) Investment tax allowance granted in relation the the Group’s hospital construction projects and capital investments

9) Professional fees relating to the Group’s acquisition of approximately 30% equity interest in Acıbadem Sağlık Yatırımları

Holding A.Ş. from a director and a substantial shareholder

10) Exchange differences arising from foreign currency denominated borrowings/payables net of foreign currency denominated

cash/receivables, recognised by Acibadem Holdings (As at 31 Dec 2018, Euro/TL=6.0280, USD/TL=5.2609)

11) Exceptional items, net of tax and non-controlling interests

As at

31 Dec 2018

As at

31 Dec 2017

RM'mil RM'mil

Total Assets 45,115 38,925

- Tangible Assets 31,176 25,955

- Intangible Assets

Goodwill 11,829 10,692

Other intangibles 2,109 2,278

Total Liabilities (16,607) (13,025)

Total Equity 28,507 25,901

Non-controlling Interests ("NCI") (4,355) (1,852)

Perpetual securities ("Perps") (2,158) (2,159)

Total Shareholders' Equity (excluding NCI and Perps) 21,994 21,890

Net Tangible Assets ("NTA") (excluding NCI and Perps) (A) 8,056 8,920

Total Debt (B) (10,535) (6,794)

Total Cash 7,763 6,079

Net Debt (C) (2,772) (715)

Net Debt / NTA (C)/(A) 0.34 0.08

Net Debt / Equity 0.10 0.03

Gross Debt / EBITDA* (times) (B)/(D) 4.25 2.98

Net Debt / EBITDA* (times) (C)/(D) 1.12 0.31

8 *: Based on last 12 months EBITDA

^: Excludes fixed deposits (>3 months) of RM170.3 million (Dec 2017: RM163.6 million)

Higher gearing post Fortis acquisition

9

Expansion Capital Expenditure – Construction & Medical Equipment

*

*

*

*

Expect to invest approx. RM2.0 billion from Q1 2019 for the Group’s hospital projects

Funded from Malaysia’s operating cash flows

and new bank facilities, if required

*: Parkway will fund its share of the project cost

through its bank facility and the hospital

business partner will fund their respective

share. Amount shown is total capex

(% indicated shows the immediate holding

company’s ownership interest in these

hospitals)

Based on the following exchange rates: 1 SGD : 3.04044 1TL : 0.78024 1 HKD : 0.53329 1 RMB : 0.60566 1 USD : 4.16570

RM' mil

Projected

Disbursements

from Q1 2019

Pantai Hospital Kuala Lumpur Expansion 65.0

Pantai Hospital Ayer Keroh Expansion 147.8

Pantai Hospital Klang Expansion 154.4

Gleneagles Medini Greenfield 91.4

458.6

Gleneagles Hong Kong Hospital - 60% Greenfield 145.4

Gleneagles Shanghai Hospital - 70% Greenfield 513.8

Gleneagles Chengdu Hospital - 70% Brownfield 420.0

933.8

Yangon Hospital - 52% Greenfield 354.1

IMU Expansion 65.4

Total Unincurred Expansion Capital Expenditure 1,957.2

Note: Based on expansion capital expenditure approved by IHH’s Board. Excludes Fortis’ hospital expansion pipeline (if any)





10

Operational Highlights

11

Q4 2018 Operational Overview

The above charts are not drawn to scale. 1. Based on Singapore, Malaysia, India and Acibadem Holdings hospitals only. Excludes hospitals operated by joint venture companies, hospitals under hospital management agreements and other international hospitals.

2. Specialist fees not included in Singapore’s and Malaysia’s average revenue per inpatient admission

3. Based on a uniform exchange rate throughout the periods shown (SGD: 3.04044; INR:0.05871; TL:0.78024)

4. Q4 2018 includes contribution from Fortis, that was acquired on 13 November 2018

Inpatient Admissions1 (Number)

IP Revenue per IP Admit1 (RM)

Q32017

Q42017

Q32018

Q42018

48,408 49,267

49,988

55,196

Malaysia

Q32017

Q42017

Q32018

Q42018

19,362 19,319

19,217

19,327

PPL - MalaysiaSingapore

Q32017

Q42017

Q32018

Q42018

50,966

57,048 54,798

57,230

PPL - MalaysiaAcibadem

Q32017

Q42017

Q32018

Q42018

29,185 29,307

31,528 31,983

PPL - MalaysiaSingapore2,3

Q32017

Q42017

Q32018

Q42018

6,509 6,413

6,678 6,653

PPL - MalaysiaMalaysia2

Q32017

Q42017

Q32018

Q42018

6,283 6,507

8,262 8,611

PPL - MalaysiaAcibadem3

Q32017

Q42017

Q32018

Q42018

20,520 18,283

16,266

39,210

PPL - MalaysiaIndia4

Q32017

Q42017

Q32018

Q42018

6,834

7,400

7,969

6,890

PPL - MalaysiaIndia3,4

Q4 YoY Growth 0.0% Q4 YoY Growth 12.0% Q4 YoY Growth 114.5% Q4 YoY Growth 0.3%

Q4 YoY Growth 9.1% Q4 YoY Growth 3.7% Q4 YoY Growth -6.9% Q4 YoY Growth 32.3%

12

Hospital Expansion Pipeline

1 projects due

for completion

in 2023

1 projects due

for completion

in 2019

2 projects due

for completion in

2020

Country Type Hospital Description

Yangon Greenfield Parkway Yangon Hospital 100 beds capacity


China Greenfield Gleneagles Chengdu 350 bed capacity


Malaysia Expansion Pantai Hospital Ayer Keroh 160 bed capacity

China Greenfield Gleneagles Shanghai 450 bed capacity

1 projects due

for completion

in 2021


Malaysia Expansion Pantai Hospital Klang 140 bed capacity

Note: Based on expansion capital expenditure approved by IHH’s Board (Refer to page 9). Excludes Fortis’ hospital expansion pipeline (if any)





13

Key Takeaways

14

Q4 2018 PATMI (Excl EI) up 88% to RM341.5 million on stronger operational performance;

FY 2018 PATMI (Excl EI) up 73% to a record RM1,027.6 billion, while headline PATMI must be seen

against strong FY 2017 that had one-off gain from disposal of Apollo stake;

IHH has executed on several fronts:

India: Added Fortis to IHH’s portfolio in November 2018 and successfully completed RHT

acquisition in January 2019

Turkey: Acting on firm plans to undertake debt restructuring to reduce Acibadem’s foreign

currency debt

Hong Kong: Continues to execute on its ramp up plans with the expansion of cardiology clinic

and health screening center to meet increasing patient’s demand

Solid performance and balance sheet enables Board to recommend a dividend of 3 sen per ordinary

share, even as IHH remains in the growth phase

Positioning for sustainable growth through a differentiated portfolio strategy to maintain leadership,

innovate, while driving organic operations

Enhance service offerings to improve clinical outcomes and increase operational efficiency

Strong Q4 and FY 2018 Performance

Driving sustainable growth to deliver long-term value

Key Takeaways





15

Questions & Answers





16

Supplementary slides

17

Contribution across the Group

RM'mil

PPL-Singapore

PPL-Malaysia

PPL-China

PPL-HK

PPL-India

PPL-Others

Acibadem Holdings

IMU Health

REIT

Others

Check to highlights

Others, -16%

REIT, 13%

IMU Health, 9%

Acibadem Holdings, 11%

PPL-Others, -11%

PPL-India, -11%

PPL-HK, -54%

PPL-China, 4%

PPL-Malaysia, 43%

PPL-Singapore, 112%

-100% -50% 0% 50% 100% 150%

Others, 0%

REIT, 1%

IMU Health, 2%


PPL-Others, 2%

PPL-India, 7%

PPL-HK, 3%

PPL-China, 2%

PPL-Malaysia, 18%

PPL-Singapore, 34%

0% 10% 20% 30% 40%

Others, 0%

REIT, 1%

IMU Health, 2%


PPL-Others, 2%

PPL-India, 6%

PPL-HK, 1%

PPL-China, 2%

PPL-Malaysia, 16%

PPL-Singapore, 35%

0% 10% 20% 30% 40%

Others, -2%

REIT, 12%

IMU Health, 4%


PPL-Others, 1%

PPL-India, 1%

PPL-HK, -13%

PPL-China, 2%

PPL-Malaysia, 23%

PPL-Singapore, 47%

-20% -10% 0% 10% 20% 30% 40% 50%

Others, -3%

REIT, 13%

IMU Health, 3%


PPL-Others, 0%

PPL-India, 0%

PPL-HK, -7%

PPL-China, -1%

PPL-Malaysia, 23%PPL-Singapore,

46%

-20% -10% 0% 10% 20% 30% 40% 50%

Others, -3%

REIT, 8%

IMU Health, 5%


PPL-Others, -3%

PPL-India, -2%

PPL-HK, -22%

PPL-China, -2%

PPL-Malaysia, 33% PPL-Singapore, 76%

-40% -20% 0% 20% 40% 60% 80% 100%

YTD 2018 PATMI (Excl EI)

YTD 2017 PATMI (Excl EI)

YTD 2018 Revenue YTD 2018 EBITDA

YTD 2017 Revenue YTD 2017 EBITDA

18


Revenue 3,131.6 2,852.2 10% 11,387.8 11,008.6 3%

EBITDA 603.9 541.2 12% 2,156.0 1,996.8 8%

PATMI 475.6 79.6 NM 541.9 893.9 -39%

PATMI (Excl EI) 307.7 160.3 92% 941.8 519.2 81%

QTD Dec YTD DecExcluding PLife REIT’s Results

Sustained organic growth from healthcare operations

19

Revenue QoQ & YoY Comparison

1: Relates to external revenue only.

It excludes PLife REIT’s rental income earned from Parkway Pantai. Similarly, it excludes Parkway Pantai’s dividend and management fee income earned from PLife REIT.

*: PPL Others comprise mainly Parkway Pantai’s hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

^: Others comprise mainly IHH Group’s corporate office as well as other investment holding entities

@ : India (Fortis) includes contribution from Northern TK Ventures Pte Ltd, immediate holding company of Fortis

Revenue1

Q4 2018 Q3 2018 Variance Q4 2018 Q4 2017 Variance YTD 2018 YTD 2017 Variance

RM'mil RM'mil % RM'mil RM'mil % RM'mil RM'mil %

Parkway Pantai:

- Singapore 1,027.5 986.9 4% 1,027.5 965.4 6% 3,890.7 3,848.3 1%

- Malaysia 551.1 503.1 10% 551.1 472.7 17% 2,019.8 1,836.4 10%

- India (Fortis@

) 217.1 - - 217.1 - - 217.1 - -

- India 139.7 161.8 -14% 139.7 176.4 -21% 634.2 708.6 -11%

- North Asia 47.4 45.7 4% 47.4 60.9 -22% 209.5 255.4 -18%

- North Asia (New)

92.2 72.6 27% 92.2 38.1 142% 290.1 77.2 NM

- PPL Others* 50.9 49.4 3% 50.9 44.7 14% 188.9 176.6 7%

Parkway Pantai 2,125.8 1,819.4 17% 2,125.8 1,758.1 21% 7,450.4 6,902.6 8%

Acibadem Holdings 817.8 808.3 1% 817.8 915.9 -11% 3,233.1 3,546.1 -9%

Acibadem Holdings(New)

122.2 114.2 7% 122.2 118.7 3% 443.1 307.4 44%

Acibadem Holdings 940.0 922.5 2% 940.0 1,034.5 -9% 3,676.2 3,853.5 -5%

IMU Health 64.4 64.4 0% 64.4 59.0 9% 257.5 250.4 3%

IHH Others^ 1.4 1.1 29% 1.4 0.6 147% 3.6 2.1 71%

GROUP (Excl REIT) 3,131.6 2,807.4 12% 3,131.6 2,852.2 10% 11,387.8 11,008.6 3%

PLife REIT Total 85.4 84.8 1% 85.4 85.1 0% 335.7 342.3 -2%

Less: PLife REIT Inter-segment (51.6) (51.2) -1% (51.6) (52.1) 1% (202.5) (208.3) 3%

PLife REIT 33.8 33.5 1% 33.8 32.9 3% 133.2 134.0 -1%

GROUP 3,165.3 2,840.9 11% 3,165.3 2,885.1 10% 11,520.9 11,142.6 3%

Q-on-Q QTD Y-on-Y YTD Y-on-Y

20

Revenue Q4 revenue eroded by strengthening RM

Revenue Variance (RM’mil)

The above figures excludes PLife REIT

Actual@ Constant

Currency

Parkway Pantai 8% 13%

Acibadem Holdings -5% 32%

IMU Health 3% 3%

IHH Group (Excl PLife REIT) 3% 19%

YTD'18 vs YTD'17

Revenue - QTD Variance

Revenue - YTD Variance

11,008.6

869.4

321.6

1,229.9

1,407.2

7.2 1.5 11,387.8

YTD 2017 Parkway Pantai Parkway Pantai(TranslationDifference)

AcibademHoldings

AcibademHoldings

(TranslationDifference)

IMU Health Others YTD 2018

2,852.2

449.6

81.8

354.2

448.7

5.4 0.83,131.6

QTD 2017 Parkway Pantai Parkway Pantai(TranslationDifference)

AcibademHoldings

AcibademHoldings


IMU Health Others QTD 2018

Actual@ Constant

Currency



IMU Health 9% 9%


Q4'18 vs Q4'17

21

EBITDA QoQ & YoY Comparison

1: Relates to the EBITDA performance of each SBUs. After elimination of dividend income from within the Group

2: Includes rental expense incurred for lease of hospitals from PLife REIT

3: Includes rental income earned from lease of hospitals to Parkway Pantai

*: PPL Others comprise mainly Parkway Pantai’s hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

^: Others comprise mainly IHH Group’s corporate office as well as other investment holding entities

@: India (Fortis) includes contribution from Northern TK Ventures Pte Ltd, immediate holding company of Fortis

EBITDA1

Q4 2018 Q3 2018 Variance Q4 2018 Q4 2017 Variance YTD 2018 YTD 2017 Variance

RM'mil RM'mil % RM'mil RM'mil % RM'mil RM'mil %

Parkway Pantai:

- Singapore2

320.7 301.5 6% 320.7 270.5 19% 1,143.2 1,060.9 8%

- Malaysia 167.0 150.0 11% 167.0 128.6 30% 578.5 513.8 13%

- India (Fortis@

) 13.3 (0.0) NM 13.3 - - 13.3 - -

- India (11.2) 0.6 NM (11.2) 9.7 NM (7.0) 13.7 -151%

- North Asia (8.3) (4.6) -82% (8.3) 9.0 -192% (7.6) 49.0 -116%

- North Asia (New)

(46.4) (55.0) 16% (46.4) (72.0) 36% (201.1) (300.9) 33%

- PPL Others* (3.2) 4.2 -177% (3.2) (28.5) 89% (1.2) 12.7 -109%

Parkway Pantai 431.9 396.7 9% 431.9 317.3 36% 1,518.2 1,349.1 13%

Acibadem Holdings 136.4 101.5 34% 136.4 167.1 -18% 470.9 548.5 -14%

Acibadem Holdings(New)

43.8 38.5 14% 43.8 39.0 12% 146.4 69.4 111%

Acibadem Holdings 180.2 140.0 29% 180.2 206.1 -13% 617.3 617.9 0%

IMU Health 9.6 25.4 -62% 9.6 7.0 38% 84.9 80.6 5%

IHH Others^ (17.8) (12.9) -38% (17.8) 10.9 NM (64.4) (50.8) -27%

GROUP (Excl REIT) 603.9 549.2 10% 603.9 541.2 12% 2,156.0 1,996.8 8%

PLife REIT3

120.1 67.6 78% 120.1 74.5 61% 321.7 282.7 14%

GROUP 724.1 616.8 17% 724.1 615.7 18% 2,477.7 2,279.5 9%

Q-on-Q QTD Y-on-Y YTD Y-on-Y

22

EBITDA Variance (RM’mil)

The above figures excludes PLife REIT

EBITDA Q3 EBITDA eroded by stronger RM

Actual@ Constant

Currency


Acibadem Holdings 0% 38%

IMU Health 5% 5%


YTD'18 vs YTD'17

EBITDA - QTD Variance

EBITDA - YTD Variance

Parkway Pantai

Acibadem Holdings

IMU Health

IHH Group (Excl PLife REIT)

Check:

1,996.8

206.0

36.9

235.7

236.3

4.3

13.6

2,156.0

YTD 2018 Parkway Pantai Parkway Pantai(TranslationDifference)

AcibademHoldings

AcibademHoldings


IMU Health Others YTD 2018

541.2

123.5

8.8

57.8

83.7

2.6

28.7

603.9

QTD 2017 Parkway Pantai Parkway Pantai(TranslationDifference)

AcibademHoldings

AcibademHoldings


IMU Health Others QTD 2018

Actual@ Constant

Currency



IMU Health 38% 38%


Q4'18 vs Q4'17

23

Strong operating cash flows Support annual dividends and capital expenditure for expansion

Cashflows @ 31 December 2018 (RM’mil)

Cash Reconciliation to Cashflow Statement: RM'mil

Cash per Balance Sheet 7,763

Less:

Bank overdrafts (81)

Cash collateral received (1)

Fixed deposits pledged (1,971)

Cash per Cashflow Statement 5,711

6,078

1,856

1,250

1,041

695,711

Cash @ 1 Jan 2018 Net cash fromOperating Activities

Net cashfrom InvestingActivities

Net cash from FinancingActivities

Effect of FX Cash @ 31 Dec 2018

Cash Debt

@ 31 Dec 2018 RM'mil @ 31 Dec 2018 RM'mil

Parkway Pantai 6,423 Parkway Pantai 6,347

Acibadem Holdings 74 Acibadem Holdings 3,505

IMU Health 70 IMU Health 0

Others 1,300 Others (0)

7,866 9,852

PLife REIT 67 PLife REIT 683

7,934 10,535

(170)

7,763

Less:

Fixed Deposits placed for 3

months or more

Documents

Results Briefing Analyst Presentation 4Q & FY2018